dna gyrase

Alalevonadifloxacin is a DNA gyrase and DNA topoisomerase inhibitor and a novel antibacterial compound of the quinolone class targeting MRSa. Alalevonadifloxacin is potentially useful in the treatment of bacterial Gram-positive, Gram-negative and anaerobic infections.

Ciprofloxacin monohydrochloride (Bay-09867 hydrochloride) is a broad-spectrum antimicrobial carboxyfluoroquinoline.

Enoxacin hydrate (AT-2266 hydrate) is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent.

Novobiocin Sodium (Albamycinsodium) binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. Novobiocin sodium is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin.

Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone that strongly inhibits the DNA-supercoiling activity of DNA gyrase.

Norfloxacin (MK-0366)(Norxacin) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Levofloxacin hydrate (Cravit hydrate) is a broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.

Sparfloxacin (CI-978) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, thus preventing DNA replication and transcription.

Trovafloxacin, a broad-spectrum quinolone antibiotic, exhibits potent activity against Gram-positive bacteria.

Gemifloxacin mesylate (Gemifloxacin mesylate) inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria.

Balofloxacin, a quinolone antibiotic, can inhibit the synthesis of bacterial DNA by interfering with the DNA gyrase.

Nalidixic acid (NSC-82174) is a synthetic 1, 8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE.

Levofloxacin ((-)-Ofloxacin) is a synthetic fluoroquinolone antibiotic that inhibits the superhelical activity of bacterial DNA rotamase and prevents DNA replication. Levofloxacin is a broad-spectrum antibiotic used for the treatment of a wide range of bacterial infections.

DNA Gyrase-IN-12 (Compound 6d) is an inhibitor of DNA gyrase. It exhibits antibacterial activity with MIC values ranging from 0.031 to 0.0625 μg mL against Vancomycin-Intermediate Staphylococcus aureus (VISA) and Enterococcus faecium.

DNA Gyrase-IN-13 (compound 1b) is an inhibitor of DNA gyrase with bacteriostatic properties. It exhibits an IC50 of 1.81 μM against Staphylococcus aureus DNA gyrase.

DNA Gyrase DHFR-IN-1 is a dual inhibitor targeting bacterial DNA gyrase and DHFR, with IC50 values of 182 μM and 3.90 μM against E. coli DNA gyrase and DHFR, respectively. This compound exhibits both bactericidal and antifungal activities.

DNA gyrase Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV with antibacterial properties. It exhibits IC50 values of 11 and 17 nM against the DNA gyrase of Escherichia coli and methicillin-resistant Staphylococcus aureus, respectively, and IC50 values of 83 and 21 nM against topoisomerase IV of the same organisms. DNA gyrase Topo IV-IN-1 is applicable in anti-infective research.

DNA Gyrase-IN-15 (Compound 11) is an antibacterial agent that inhibits both DHPS and DNA gyrase, with IC50 values of 1.73 and 0.07 µM, respectively. It shows antimicrobial activity against Enterococcus faecium (MIC of 15.62 µg mL), Acinetobacter baumannii, Enterobacter (MIC of 7.81 µg mL), Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, DNA Gyrase-IN-15 exhibits antibiofilm activity against Enterococcus faecium.

DNA Gyrase-IN-16 (Compound 9) is an inhibitor of DNA gyrase, with an IC50 of 1.609 μM. It exhibits antibacterial properties, effectively inhibiting S. aureus and MRSA, with a MIC of 3.125 μM for both.

DNA Gyrase-IN-17 (Compound 5C) is an inhibitor of DNA gyrase. It demonstrates significant antimicrobial activity against a range of Gram-positive and Gram-negative strains, including Enterococcus faecium, Escherichia coli, and Pseudomonas aeruginosa, with a MIC value of 62.5 μg/mL. By inhibiting bacterial DNA gyrase, DNA Gyrase-IN-17 disrupts DNA replication. This compound can be useful in the development of antibiotics, particularly for studying resistant strains.

DNA Gyrase-IN-3 (Compound 28) is an inhibitor of bacterial DNA gyrase B with an IC50 of 5.41-15.64 μM for inhibiting Escherichia coli DNA rotatase. It exhibits both anti-tuberculosis and antibacterial activity.

14α-Demethylase DNA Gyrase-IN-2 (Compound 6a) is a potent inhibitor of 14α-Demethylase and DNA Gyrase, exhibiting significant antibacterial activity.

14α-Demethylase DNA Gyrase-IN-1 (Compound 7c) is a potent inhibitor of 14α-Demethylase DNA Gyrase, exhibiting antibacterial activity.

DNA Gyrase-IN-4 (compound 8p) is a potent inhibitor of DNA cyclooxygenase (IC50: 0.13 μM) and exhibits significant antimicrobial activity with minimum inhibitory concentrations (MIC) of 0.05 μg ml against Salmonella and 8 μg ml against Escherichia coli.